YKL-40 and Complications in Type 2 Diabetes

This study has been completed.
Sponsor:
Collaborator:
National Science Council, Taiwan
Information provided by:
National Taiwan University Hospital
ClinicalTrials.gov Identifier:
NCT01387984
First received: July 1, 2011
Last updated: July 5, 2011
Last verified: June 2011
  Purpose

In this study, the investigators plan to establish the relationship between plasma concentration of YKL-40 with various vascular complications in the patients of type 2 diabetes.


Condition
Type 2 Diabetes Mellitus

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Cross-Sectional
Official Title: Association Study of the Plasma Concentration of YKL-40 and Vascular Complications in Patients With Type 2 Diabetes

Resource links provided by NLM:


Further study details as provided by National Taiwan University Hospital:

Enrollment: 473
Study Start Date: April 2010
Study Completion Date: April 2010
Primary Completion Date: April 2010 (Final data collection date for primary outcome measure)
Groups/Cohorts
Type 2 diabetes mellitus

Detailed Description:

It is well recognized now that diabetes mellitus is a systemic vasculopathy and causes various micro- and macrovascular complications. Vascular damage and endothelium dysfunction in diabetes mellitus involve a chronic inflammatory process via a complicated mechanism.

YKL-40 is a 40 kD lectin molecule. It is secreted by various cells, including macrophages, vascular smooth muscle cells and giant cells, and the level of YKL-40 is found elevated in both acute (eg. infection) and chronic (eg. rheumatoid arthritis, systemic lupus erythematosus or cirrhosis of the liver) inflammatory processes. The plasma concentration of YKL-40 is elevated in the patients of type 2 diabetes mellitus compared with non-diabetic controls, and is associated with insulin resistance, fasting plasma glucose and plasma IL-6 concentrations. Furthermore, the concentration of YKL-40 is elevated and is associated with the severity of albuminuria in the patients of type 1 diabetes.

The objective of this study is to establish the relationship between plasma concentration of YKL-40 with various vascular complications in the patients of type 2 diabetes, and to evaluate its potential as a biomarker for the vascular diabetic complications in patients with type 2 diabetes.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

The type 2 diabetic patient who receives follow-up at NTUH diabetics caring network

Criteria

Inclusion Criteria:

  • Clear consciousness
  • type 2 diabetic patient
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01387984

Locations
Taiwan
National Taiwan University Hospital Yun-Lin Branch
Douliu City, Yunlin County, Taiwan, 640
Sponsors and Collaborators
National Taiwan University Hospital
National Science Council, Taiwan
Investigators
Principal Investigator: Chih-Hung Lin, M.D. National Taiwan University Hospital, Yun-Lin Branch
  More Information

No publications provided

Responsible Party: Chih-Hung Lin, MD, National Taiwan University Hospital Yun-Lin Branch
ClinicalTrials.gov Identifier: NCT01387984     History of Changes
Other Study ID Numbers: 201002053R
Study First Received: July 1, 2011
Last Updated: July 5, 2011
Health Authority: Taiwan: Department of Health

Keywords provided by National Taiwan University Hospital:
Type 2 diabetes mellitus
Diabetic complications
YKL-40

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases

ClinicalTrials.gov processed this record on August 21, 2014